◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Suven Life Sciences Limited (SUVEN) Financial History

Name: Suven Life Sciences Limited (SUVEN) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Suven Life Sciences Limited (SUVEN) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hyderabad, India with about 142 employees. Its market capitalization is roughly ₹97 billion. In the fiscal year ended 2026-03-31, SUVEN reported ₹71M in revenue and (₹2.8B) in net income.

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally.

Interactive charts & full statements →

SUVEN Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹71M	₹67M	₹117M	₹135M	—
Gross Profit	₹61M	₹56M	₹110M	₹132M	—
Operating Income (EBIT)	(₹2.9B)	(₹1.7B)	(₹1.3B)	(₹1.3B)	—
Net Income	(₹2.8B)	(₹1.6B)	(₹1.1B)	(₹1.2B)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUVEN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹36M	₹15M	₹28M	₹9M	₹19M	—
Gross Profit	₹36M	₹15M	₹28M	₹9M	₹19M	—
Operating Income (EBIT)	(₹1.3B)	(₹522M)	(₹1.0B)	(₹811M)	(₹521M)	—
Net Income	(₹1.3B)	(₹456M)	(₹1.0B)	(₹773M)	(₹515M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUVEN Free Cash Flow History

SUVEN Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹6.2B	₹1.4B	₹2.8B	₹3.9B	—
Total Liabilities	₹328M	₹252M	₹149M	₹136M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SUVEN viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

AKUMS · Akums Drugs and Pharmaceuticals Limited — ₹120 billion
4534 · Mochida Pharmaceutical Co., Ltd. — JPY 116 billion
STAR · Strides Pharma Science Limited — ₹112 billion
VIYASH · Viyash Scientific Limited — ₹110 billion
PGHL · Procter & Gamble Health Limited — ₹91 billion
4559 · Zeria Pharmaceutical Co., Ltd. — JPY 89 billion
AARTIPHARM · Aarti Pharmalabs Limited — ₹74 billion
BLISSGVS · Bliss GVS Pharma Limited — ₹73 billion

← SUUS All “S” companies SUVIDHAA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.